1795P China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Autor: | Zhou, F., Gongqian, Z., Guo, H., Hu, Z., Zhang, X., He, D., He, Z., Zhang, D., Li, Y., Kadeerbai, H., Liu, Y., Ye, D. |
---|---|
Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S971-S971 |
Databáze: | ScienceDirect |
Externí odkaz: |